TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Tailored Messages to Increase Eye Examination Behavior
Brief Summary: The purpose of this project is to test two different types of health messages, one that is developed for a specific group (targeted) and the other that is more personalized to individuals (tailored), to see which is better at changing how often people have their eyes examined. We hypothesize that people who get the tailored messages will be more likely to get a dilated eye exam than people who receive the targeted messages.


Options:
A: Pt. 1

Inclusion Criteria:

* African-American race (self-identified)
* Age ≥ 65 years
* Type II Diabetes Mellitus (physician diagnosis) for at least 1 year
* No medical documentation of a DFE by an ophthalmologist or an optometrist within the past 12 months
* Self-report of no DFE within the past 12 months

Exclusion Criteria:

* Cognitive Impairment (Mini-Mental Status Examination ≤ 24)
* Current clinically significant psychiatric disorder other than depression
* Current medical disorder that limits life expectancy (≤ 12 months) or need for dialysis
* Hearing impairment that precludes research participation

Pt. 2

Inclusion Criteria:

* Glaucoma (physician diagnosis)
* Scheduled for a follow-up appointment that meets the American Academy of Ophthalmology (AAO) follow-up guidelines
* Attended the Wills Eye Glaucoma Clinic from September 1, 2012 to October 31, 2013
* Age ≥ 21 years old
* Able to understand and speak English

Exclusion Criteria:

* Diagnosed with a pre-existing medical condition that would preclude the subject from providing reliable and valid data
* Individual was asked to follow-up in less than a month.
B: Inclusion Criteria:

* Established T1D diagnosis for a minimum of one year (chosen to allow time for adjustment to a new diagnosis and more stable disease control).
* Between the ages of 17 and 20 years. It is left to the clinical judgment of the pediatric endocrinologist to determine individually the appropriate age of the transition for each subject
* At least 1 visit during the previous year with the pediatric endocrinologist at a Diabetes Clinic (aim is to minimize the non-adherence with the intervention).
* Ability to participate in all aspects of this clinical trial.
* Written informed consent/assent must be obtained and documented.
* Resident of Ontario.

Exclusion Criteria:

* Pregnant or lactating females or intent to become pregnant during the next 3 years.
* Conditions which in the opinion of the investigator may interfere with the subject's ability to participate in the study.
* Prior enrollment in the current study.
* Current participation in another clinical trial or participation in another clinical trial in the 6 months prior to enrollment.
C: Inclusion Criteria:

* African-American
* 65 years of age or older
* no dilated fundus exam in past 2 years

Exclusion Criteria:

* appointment for dilated fundus exam scheduled
* no access to phone
D: Inclusion Criteria:

* diabetic, at least 18 years old, patient at a participating health clinic

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Clinical and Genomic Responses to Open Heart Surgery: A Randomized Controlled Trial of the Effects of Remote Ischemic Preconditioning
Brief Summary: This study will be the first large scale randomized study of remote ischemic preconditioning (RIPC) ever performed and will define the role of this novel therapy as a clinical tool. This study will also be the first to define preoperative gene expression profiles associated with poor postoperative outcomes in a control (SHAM) population of children undergoing cardiac surgery. Finally, the role of RIPC in modifying these gene expression profiles will be examined. Therefore, mechanistic insight into the proven ability of RIPC to improve markers of tissue injury, and the expected improvement in clinically relevant endpoints, will be examined.


Options:
A: Inclusion Criteria:

* perimembranous or muscular outlet or muscular inlet ventricular septal defect
* pulmonary hypertension (+)
* infant (\<1 year)

Exclusion Criteria:

* subarterial ventricular defect
* chromosomal defect
* airway or parenchymal lung disease
* blood disorder
* anticipation of cardiac muscle resection
B: Inclusion Criteria:

* Subject age birth (\>36 weeks gestation) to 17 years.
* Underlying cardiac anatomy and planned primary repair with no anticipated residual shunting. Repair must necessitate use of cardiopulmonary bypass.
* Informed consent/assent of subject, parent(s) or legal guardian as appropriate.

Exclusion Criteria:

* Current or recent ischemic insult, defined as vascular occlusion or episode of cardiorespiratory collapse requiring medical intervention occurring within 7 days of enrollment.
* Evidence in any system for organ dysfunction that requires medical intervention.
* Current treatment with systemic anticoagulation therapy or the presence of a bleeding diathesis.
* Presence of important pulmonary or airway disease requiring medical intervention.
* Current or previous (within 10 days of screening) use of systemic corticosteroids.
* Recent (within 7 days of screening) or current documented systemic infection or sepsis.
* Anticipated unavailability of an uninstrumented limb with no anatomic or physiologic abnormality precluding administration of RIPC stimulus using a standard blood pressure cuff.
C: Inclusion Criteria:

* LV ejection fraction \<40%
* NYHA functional class II-IV
* Non ischemic cardiomyopathy
* Stable

Exclusion Criteria:

* recent cardiovascular hospitalization (within last 4 weeks)
* ischemic cardiomyopathy
* diabetes mellitus
* peripheral neuropathy
* ventricular assist device
* contraindications to exercise stress testing
D: Inclusion Criteria:

* Patients scheduled for PCI

Exclusion Criteria:

* Acute myocardial infarction
* Myocardial infarction or coronary bypass surgery during the last 4 weeks before PCI
* Use of Glyburide
* Heart failure (NYHA III/IV)
* Chronic inflammatory disease
* Severe renal impairment
* Significant peripheral vascular disease
* Unsuitable for use of an embolic protection device for PCI to SVG

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Balancing Risk: Red Blood Cell Transfusion Strategies In Cardiac Surgery
Brief Summary: The primary purpose of this study is to determine the best blood level to begin transfusing red blood cells in individuals undergoing cardiac surgery.

The secondary aim is to determine the impact of red cell transfusion on health-related quality of life following surgery.


Options:
A: Inclusion Criteria:

* 1. Hemoglobin concentration ≤ 95 g/L, while in PICU
* 2. Not already participating to a randomized controlled trial on hemoglobin threshold to guide red blood cell transfusion practice

Exclusion Criteria:

1. Post conception age ≤ 36 weeks or \> 18 years at PICU entry
2. Refusal of consent by patient and/or parent
3. Uncorrected cyanotic cardiac disease, univentricular physiology
4. Sickle cell disease
5. Brain Death
6. Extracorporeal membrane oxygenation (ECMO)
B: Inclusion Criteria:

* Infants with a birth weight of 400 - 999g

Exclusion Criteria:

* Missing written parental consent.
* Gestational age \> 29 + 6/7 weeks
* Major congenital anomalies (including chromosomal aberrations, cyanotic congenital heart defects, syndromes likely affecting long-term outcome, and major congenital malformations requiring surgical correction during newborn period).
* Infants who died before 48 hours, infants in whom the clinical decision to withhold intensive care was made, infants who were not considered viable
* Participation in another study with ongoing use of an unlicensed investigational product from 28 days before study enrollment until the end of the study
C: Inclusion Criteria:

* All primary and reoperative adult cardiac surgical patients undergoing cardiopulmonary bypass for coronary artery bypass grafting, coronary artery bypass grafting with a valve procedure, isolated valve procedures and ascending aortic repair for aneurysm or dissection procedures.

Exclusion Criteria:

* Age less than 18 years
* Congenital procedures
* Emergencies
* descending thoracic aortic aneurysm repairs
* Left or right ventricular assist devices
* Left ventricular aneurysm resections
* Heart or lung transplantation
* Those unable to receive blood for religious reasons
D: Inclusion Criteria:

* Adults patients with cancer admitted to ICU due to severe clinical condition AND
* Septic shock diagnosis AND
* Solid neoplasm AND
* Written informed consent

Exclusion Criteria:

* Age less than 18 years OR
* Leukemia or myelodysplastic syndrome OR
* Hematologic neoplasm OR
* Palliative treatment OR
* Renal Chronic Failure in Renal Replacement Therapy OR
* Karnofsky Status \< 50 OR
* Previous thrombocytopenia (platelet number lower than 50.000/mm3) OR
* Previous known coagulopathy OR
* Life-threatening bleeding OR
* Documented wish against transfusion OR
* Patients who refused participation in the study

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Journey for Control of Diabetes Study
Brief Summary: Behavior change and self-efficacy are key for patients with diabetes to sustain blood sugar goals, but most care systems do not provide effective support to assist patients in successful ongoing self-management. After initial education, many programs are limited by allowable Medicare reimbursement for diabetes education which currently requires physician referral and cannot exceed two hours of training per year for a beneficiary, plus one hour of nutritional services. These services are usually provided either on an individual basis or occasionally through a traditional group class approach. For patients with established type 2 diabetes who are not achieving optimal glycemic control, we propose to develop and formally evaluate in a randomized trial a novel group experience to educate and motivate patients with established type 2 called IDEA, (Interactive Dialogue to Educate and Activate). This multi-site, randomized, prospective trial will randomize 621 patients with inadequately blood sugar control levels to one of 3 study groups: (1) IDEA - patients receive group sessions totaling 8 hours, with an average of 10 patients per group, using conversation maps as a conduit to facilitate dialogue between providers and patients (2) Individual Education (IE) - patients receive 2 hours with a nurse educator and 1 hour with a dietitian, and (3) Usual care (UC)- patients receive no research intervention. The primary analyses will involve mixed model regression to assess whether IDEA improves outcomes compared to IE and UC. Blood sugar level, blood pressure, and lipids will be evaluated 6 and12 months post-randomization and behavioral, emotional, and satisfaction outcomes through survey at baseline, 3, 6, 9 and 12 months. Depending on 12 month results, a longitudinal four year post intervention analysis is planned to assess sustainability of treatment effects and cost-effectiveness.


Options:
A: Inclusion Criteria:

* Type 2 Diabetes Mellitus

Exclusion Criteria:

* Gestational diabetes
* Type 1 Diabetes Mellitus
B: Inclusion Criteria:

* type 2 diabetes
* HbA1c \> 7%
* age \> 21

Exclusion Criteria:

* substance abuse disorder
* serious psychiatric illness
* serious hearing loss
* life expectancy \< 12 months
C: Inclusion Criteria:

* Diagnosis of diabetes mellitus
* Age 25-79 years
* HbA1c \>=8.5%
* Ability to speak and understand English
* Telephone access
* VA-based primary care provider
* Interest in using a glucose and BP monitor and notebook computer

Exclusion Criteria:

* Visual impairment that affects ability to read
D: Inclusion Criteria:

* At least 18 years of age
* Had physician-diagnosed type 2 diabetes
* Self-identified as African American or Latino/Hispanic
* Lived in the targeted zip codes.

Exclusion Criteria:

* Individuals who already had serious diabetes-related complications, such as blindness, amputated limbs, and kidney failure

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Modified Ritgens Maneuver for Perineal Protection at Delivery
Brief Summary: The aim of the investigation was to assess whether routine use of the modified Ritgen´s maneuver decreases the risk of anal sphincter injury at delivery, compared with simple manual protection of the perineum.Ritgen´s maneuver means that the fetal chin is reached for between the anus and the coccyx and pulled anteriorly, while using the fingers of the other hand on the fetal occiput to control speed of delivery and keep flexion of the fetal neck.


Options:
A: Inclusion Criteria:

* Women with singleton pregnancy and a fetus in cephalic presentation
* admitted for labor
* rupture of the membranes or induction after 37 completed gestational weeks
* and reaching full cervical dilatation.

Exclusion Criteria:

* Operative delivery
B: Inclusion Criteria:

* Vaginal delivery

Exclusion Criteria:

* Age below 18 years and no understanding of written and oral information.
C: Inclusion Criteria:

* With no pregnancy-related complications diagnosed during pregnancy,
* No definitive indication for C-section,
* Satisfying the pregnancy week in terms of the fetal dimensions,
* At the 37th-42nd gestation week,
* Applying to have her first or second birth,
* With no systemic condition,
* With head presentation,
* At the latent phase of the first stage of birth with a dilatation under 4 cm and effacement below 50%,
* That have provided written consent specifying their voluntariness in participating in the study.

Exclusion Criteria:

* With pregnancy-related complications diagnosed during pregnancy,
* Definitive indication for C-section,
* No satisfying the pregnancy week in terms of the fetal dimensions,
* At the \<37th- \>42nd gestation week,
* With systemic condition,
* With no head presentation,
* At the latent phase of the first stage of birth with a dilatation above 4 cm
* No have provided written consent specifying their voluntariness in participating in the study.
D: Inclusion Criteria:

* nullipara
* primipara with previous cesarean section

Exclusion Criteria:

* Multipara
* Twin pregnancies
* Nullipara with elective cesarean section
* Preterm delivery before 35 gestational weeks
* Breech delivery
* Acute cesarean section

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Modified Ritgens Maneuver for Perineal Protection at Delivery
Brief Summary: The aim of the investigation was to assess whether routine use of the modified Ritgen´s maneuver decreases the risk of anal sphincter injury at delivery, compared with simple manual protection of the perineum.Ritgen´s maneuver means that the fetal chin is reached for between the anus and the coccyx and pulled anteriorly, while using the fingers of the other hand on the fetal occiput to control speed of delivery and keep flexion of the fetal neck.


Options:
A: Inclusion Criteria:

* Singleton gestations
* Low risk pregnancies
* 37 to 42 weeks of gestations

Exclusion Criteria:

* Multiple gestations
* Preterm birth
B: Inclusion Criteria:

* nullipara
* primipara with previous cesarean section

Exclusion Criteria:

* Multipara
* Twin pregnancies
* Nullipara with elective cesarean section
* Preterm delivery before 35 gestational weeks
* Breech delivery
* Acute cesarean section
C: Inclusion Criteria:

* Low risk patients in active labor admitted to the IMIP; Gestational age between 37 and 42 weeks;
* Cephalic fetus;
* Cervical dilatation up to 8 cm at the time of inclusion in the study.

Exclusion Criteria:

* Indication of cesarean section at the time of the approach;
* Inability to understand and / or perform vocalization maneuvers.
* Patients with Dysphonia
* Deaf and mute patients
* Use of Oxytocin prior to randomization
D: Inclusion Criteria:

* Women with singleton pregnancy and a fetus in cephalic presentation
* admitted for labor
* rupture of the membranes or induction after 37 completed gestational weeks
* and reaching full cervical dilatation.

Exclusion Criteria:

* Operative delivery

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Effect of Daily Consumption of Yogurt Containing Bifidobacterium Lactis (BB12) on Children's' Health and Child Care Absenteeism
Brief Summary: The aim of our study is to assess the effect of daily consumption of yogurt containing probiotic bacteria BB12 on the health and growth of healthy children 12-48 months of age in out of home child care.


Options:
A: Inclusion Criteria:

* children aged 12-48 months attending educational program (either at nursery or primary school)

Exclusion Criteria:

* concomitant chronic/congenital diseases and disabilities,
* active tuberculosis,
* congenital cardiac defects,
* autoimmune diseases,
* immunodeficiency,
* chronic inflammatory bowel diseases,
* celiac diseases,
* cystic fibrosis,
* metabolic diseases,
* malignancy,
* chronic pulmonary diseases,
* malformation of the GI tract,
* history of allergy,
* severe wasting (less than 3 Standard deviations of weight-for-height z score),
* diarrhea on admission,
* antibiotic,
* pre/pro/symbiotic or immunostimulants use within 2 weeks before study start.
B: Inclusion Criteria:

* An informed consent has been signed by the parents.
* The child is at least one year old and has not had his 4th birthday at the beginning of the study
* The child is healthy.
* The child attends child care center at least 5 days a week, \> 4 hours per day.

Exclusion Criteria:

* Was born preterm.
* Had a birth weight \<2,500 g.
* Has congenital anomalies.
* Has a structural abnormality of the digestive tract or previous significant gastrointestinal surgery.
* Has chronic disease or malignancy.
* Has a serious, unstable medical condition.
* Is Failure to Thrive (FTT) (\<5th percentile of ideal body weight).
* Has an allergy or atopic disease.
* Has an allergy or intolerance to milk/dairy products.
* Has an established diagnosis of lactase deficiency.
* Is predisposed to infection (i.e., compromised immune system, HIV-AIDS, active bacterial disease, under steroid treatment).
* Received antibiotic treatment or intentionally consumes probiotic products during the preceding 4 weeks. (If the subject was on antibiotics before the beginning of the study or probiotics, a washout period of 2 weeks is required.)
C: Inclusion Criteria:

* 6 months old children born at term
* written consent from parents

Exclusion Criteria:

* frequent gastrointestinal disorders (frequent diarrhoeas, constipation episodes, gastroesophageal reflux)
* gastrointestinal surgery
* cow's milk protein allergy
* metabolic diseases (diabetes or lactose intolerance)
* immune deficiency
* antibiotic treatment during the trial and/or recent (within the preceding 3 weeks)
D: Inclusion Criteria:

* Healthy 1 month infants exclusively formula-fed

Exclusion Criteria:

* gastrointestinal disorders (history of chronic diarrhoea or constipation, gastroesophageal reflux)
* gastrointestinal surgery
* cow's milk protein allergy
* metabolic disorders (diabetes, lactose intolerance)
* immune deficiency
* antibiotic prescription 1-week prior to inclusion and previous use of formula containing prebiotics or probiotics

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Local Infiltration Analgesia (LIA) With Ropivacaine, Ketorolac and Epinephrine Intra- and Postoperatively in Unicompartmental Knee Arthroplasty
Brief Summary: The primary aim of this study is to evaluate if intra- and postoperative administration of ropivacaine, ketorolac and epinephrine into the operating field would affect hospital stay. Secondary end-points are morphine consumption, pain intensity and side effects. In an attempt to assess the safety of this technique, knee function and patient satisfaction scores are assessed up to 6 months after surgery.


Options:
A: Inclusion Criteria: Patient undergoing elective total hip replacement surgery, or revision thereof -

Exclusion Criteria: A definite indication or contra-indication for treatment with a NSAID during the 14-day study treatment period, in the opinion of the treating clinician.

-
B: Inclusion Criteria:

* Patients scheduled for unicompartmental knee arthroplasty
* Aged 20-80 yrs.
* ASA physical status I-III and mobility indicating normal postoperative mobilization

Exclusion Criteria:

* Known allergy or intolerance to one of the study drugs
* Serious liver-, heart- or renal decease
* Rheumatoid arthritis
* Chronic pain or bleeding disorder
C: Inclusion Criteria:

* Consecutive patients scheduled for elective minimally invasive direct coronary artery bypass (MIDCAB) or for lung resection via anterolateral thoracotomy during a 6-month period (Sep 2001-March 2002)

Exclusion Criteria:

Exclusion criteria were:

* American Society of Anesthesiologists (ASA) physical class ≥3, Emergency operations,
* Q-wave myocardial infarct occurring during the previous 3 weeks, or poor left ventricular function (e.g., ejection fraction \[EF\] \<30% by echocardiography or angiography).

Other exclusion criteria were:

* A body mass index \>35 kg/m2,
* Past or current neuropathy or psychological disturbances,
* The use of centrally active drugs,
* Chronic liver or renal failure requiring dialysis,
* A FEV1/FVC \<70%,
* Allergy to ketamine, morphine or non steroidal anti inflammatory drugs (NSAIDs),
* Clotting abnormalities,
* A platelets count \<70000/mm3,
* A white blood count \<3000\>14000/mm3,
* Uncontrolled diabetes mellitus or fasting blood glucose \>250 g/dl,
* Evidence of sepsis or infection up to one week prior to randomization.
D: Inclusion Criteria:

1. American Society of Anesthesia physical status class I \& II
2. Age ≥ 20 and ≤ 65 years
3. Robot- assisted endoscopic thyroidectomy

Exclusion Criteria:

1. Known or suspected allergy, sensitivity, or contraindication to pregabalin or any of the standardized medications
2. Body mass index ≥ 40 kg/m2
3. History of seizure disorder
4. Current therapy with pregabalin, gabapentin, or any opioid
5. Any other physical or psychiatric condition which may impair their ability to cooperate with post-operative study data collection
6. Insulin-dependent diabetes mellitus
7. Renal insufficiency (estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2)

Answer: B